Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
Planchard D, Brown KH, Kim DW, Kim SW, Ohe Y, Felip E, Leese P, Cantarini M, Vishwanathan K, Jänne PA, Ranson M, Dickinson PA. Planchard D, et al. Among authors: vishwanathan k. Cancer Chemother Pharmacol. 2016 Apr;77(4):767-76. doi: 10.1007/s00280-016-2992-z. Epub 2016 Feb 22. Cancer Chemother Pharmacol. 2016. PMID: 26902828
The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD. Vishwanathan K, et al. Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23. Br J Clin Pharmacol. 2018. PMID: 29381826 Free PMC article. Clinical Trial.
Absolute Bioavailability of Osimertinib in Healthy Adults.
Vishwanathan K, So K, Thomas K, Bramley A, English S, Collier J. Vishwanathan K, et al. Clin Pharmacol Drug Dev. 2019 Feb;8(2):198-207. doi: 10.1002/cpdd.467. Epub 2018 Apr 23. Clin Pharmacol Drug Dev. 2019. PMID: 29683562 Clinical Trial.
Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
Harvey RD, Aransay NR, Isambert N, Lee JS, Arkenau T, Vansteenkiste J, Dickinson PA, Bui K, Weilert D, So K, Thomas K, Vishwanathan K. Harvey RD, et al. Among authors: vishwanathan k. Br J Clin Pharmacol. 2018 Dec;84(12):2877-2888. doi: 10.1111/bcp.13753. Epub 2018 Oct 10. Br J Clin Pharmacol. 2018. PMID: 30171779 Free PMC article.
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer.
Varrone A, Varnäs K, Jucaite A, Cselényi Z, Johnström P, Schou M, Vazquez-Romero A, Moein MM, Halldin C, Brown AP, Vishwanathan K, Farde L. Varrone A, et al. Among authors: vishwanathan k. J Cereb Blood Flow Metab. 2020 Apr;40(4):799-807. doi: 10.1177/0271678X19843776. Epub 2019 Apr 20. J Cereb Blood Flow Metab. 2020. PMID: 31006308 Free PMC article.
131 results